E-MAIL UPDATES

Click here to join

Investors & Media

What's new.

Press releases

Press releases.

Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC

August 1st 2022
press releases

Immutep Quarterly Activities Report

July 28th 2022
press releases

Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

July 6th 2022
press releases

Investor updates

Investor updates.

Investor Update ASCO 2022 Special Edition June 2022

June 17th 2022
investor updates

Investor Update - February 2022

February 18th 2022
investor updates

Investor Update - April 2021

April 14th 2021
investor updates

Analyst reports

Analyst reports.

Maxim Group - Interim Data from TACTI-002 Study to be Presented at World Conference on Lung Cancer, Aug 6-9 (Analyst: Jason McCarthy)

For a copy of this analyst report please contact your Maxim analyst Jason McCarthy - jmccarthy@maximgrp.com

August 2nd 2022
analyst reports

Wilsons Equity Research - Chemo-free efficacy – yes please! (ASX:IMM) (Analysts: Dr Melissa Benson and Dr Shane Storey)

August 1st 2022
analyst reports

Ladenburg Thalmann - One Drug, Multiple Late-stage Opportunities; Reiterate Buy Rating (NASDAQ:IMMP) (Analyst: Dr Ahu Demir)

For a copy of this research report please contact your Ladenburg advisor.

August 1st 2022
analyst reports